Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
Follicular Lymphoma|Marginal Zone Lymphoma|B-Cell Lymphoma
DRUG: Zanubrutinib|DRUG: Rituximab
Overall Response Rate: Cohort A, Overall response rate will be determined using a 5 point scale per the Lugano criteria., Up to 6 Months|Overall Response Rate: Cohort B, Overall response rate will be determined using a 5 point scale per the Lugano criteria., Up to 6 Months
Efficacy of Zanubrutinib and Rituximab, Time to event endpoints (Progression free survival, Overall survival, duration of response, time to next anti-lymphoma therapy) will be summarized by Kaplan-Meier method for each cohort., Up to 24 months|Safety and tolerability of combination Zanubrutinib and Rituximab, Safety and tolerability of the combination use of zanubrutinib and rituximab will be summarized descriptively by frequencies and percentages. Statistics will be given on type, severity, frequency, and attribution of adverse events., Up to 24 Months
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).